Screening

Explore the definitive findings of the "European Study of Prostate Cancer Screening — 23-Year Follow-up" to understand how long-term prostate cancer screening significantly impacts patient survival. Maurie Markman, MD, provides a detailed analysis of this landmark study, highlighting a 13%...

This expert panel discussion at the Southwest Prostate Cancer Symposium explores how prostate cancer screening and diagnostic decisions are made in real clinical practice. The conversation begins by discussing historical prostate-specific antigen (PSA) thresholds and why PSA alone is...

Department of Medicine Grand Rounds, February 20, 2026 Presented by Dr. Rachel Issaka Associate Professor, Division of Gastroenterology Kathryn Surace-Smith Endowed Chair in Health Equity Research Director, FHCRC/UW Medicine Population Health Colorectal Cancer Screening Program University of...

* “The bladder is a solitary organ we cannot transplant. Protecting it should be a national priority. If 1 in 3 men will suffer bladder consequences by age 65, bladder health screening is not optional. It is a public health responsibility,” Kuang says. * Although the medical community has made...

08:00 What Happens After an Elevated PSA In this episode, Dr. Rena Malik, MD and Dr. Scott Eggener explore the complexities of prostate cancer screening, discussing personalized risk assessment, PSA testing, and the evolving guidelines on when to start and stop screening. They break down...

In this edition of EAUTV on Day 3 at EAU26 in London, our panel of experts discussed prostate cancer screening and AI-assisted diagnosis. Moderator Prof. Veeru Kasivisvanathan (GB) and Dr. Sigrid Carlsson (DE), Prof. Jonas Hugosson (SE), Dr. Maarten de Rooij (NL) discussed the Gothenburg study...

One of the true heavyweights in the field here! https://cancer.umn.edu/staff/emmanuel-antonarakis https://www.urotoday.com/video-lectures/advanced-prostate-cancer/video/5408-practical-approaches-to-genetic-testing-in-metastatic-hormone-sensitive-prostate-cancer-emmanuel-antonarakis.html...

Is the biopsy needle more dangerous than the cancer itself? In this episode, Dr. Geo sits down with Dr. Mark Emberton, Dean of Medical Sciences at UCL and a global leader in urologic oncology. We dive deep into the "See and Treat" revolution—a massive shift in prostate cancer care that moves...

We have relied on PSA for decades, but what’s next in precision screening for prostate cancer? In this episode of BackTable Urology, Dr. Jason Hafron from the Michigan Institute of Urology joins host Dr. Ruchika Talwar to discuss the evolving role of biomarkers and artificial intelligence in...

* Dr. Carlsson asserts that prostate cancer screening is moving toward integrated, risk-adapted models, combining PSA, biomarkers, imaging, and AI to optimize outcomes for men globally. Dr. Sigrid Carlsson, MD, PhD, MPH, Head, Division of Clinical Epidemiology of Early Cancer Detection...

In this compelling episode, cardiologists John M. Mandrola, MD, and Axel Diederichsen, MD, PhD, discuss the groundbreaking findings of the Dancavas 2 trial presented at the European Society of Cardiology meeting. Building on the previous Dancavas 1 study, this new research investigates the...

This video is part one of a four-part series where we review helpful screening and diagnostic tools for prostate cancer. This video highlights the basics of prostate cancer, its risk factors and how early screenings can help. Chapters 00:07: What is prostate cancer? 01:13: What are the risk...

Introduction Men remain at risk for prostate cancer after simple prostatectomy. Despite our understanding of this, no parameters exist to inform urologists of prostate specific antigen (PSA) monitoring after surgery. This study aimed to compare initial postoperative PSA measurements and PSA...

FIGURE 1 Direct and indirect mechanisms by which opioids cause hypogonadism. +, stimulation; -, inhibition; FSH, follicle-stimulating hormone; GnRH, gonadotropin-releasing hormone; LH, luteinizing hormone; PRL, prolactin; T, testosterone. Opioid-induced androgen deficiency in men...

In the video, Dr. Marshalls, a medical oncologist with 30 years of experience in prostate cancer, discusses various blood tests used for prostate cancer screening. He explains the limitations of PSA (Prostate-Specific Antigen) tests, which can indicate issues with the prostate gland but are not...

ABSTRACT Objective Individuals with opioid use disorder (OUD) have reduced life expectancy and inferior outcomes when treated for depression, diabetes, and fractures. Their elevated risk of testosterone deficiency may contribute to all of these relationships, however few individuals prescribed...

19:38-32:10 Summary This virtual talk on men's health focused on the disparities in healthcare utilization between men and women, as well as the importance of early intervention and lifestyle choices. It also highlighted the prevalence of Peyronie's disease and the available treatments...

Convincing your PCP partners to screen for the early warning signs of prostate cancer does not have to be complicated. Learn how to develop an easy-to-follow risk stratification pathway to share with your PCP partners in this 12-minute talk from E. David Crawford, MD, Editor-in-Chief of Grand...

How can we make prostate cancer screenings more helpful? Prof. Hendrik Van Poppel, MD, PhD has performed more than 2500 radical prostatectomies. For eight years, he had been the director of the European School of Urology (ESU), before becoming EAU Adjunct Secretary General, responsible for...

Sigrid Carlsson, MD, Ph.D., MPH, Assistant Attending Epidemiologist at Memorial Sloan Kettering Cancer Center (MSKCC), discusses the current state of prostate cancer screening, focusing on PSA screening, risk calculators, biomarkers, and MRI. While not a perfect tool, PSA screening reduces...

https://www.pbs.org/video/fighting-cancer-1673641476/ Cancer deaths in the United States have dropped 33% in the past three decades, according to a report from the American Cancer Society. Cervical cancer rates dropped 65% for women in their early 20s, but there are troubling signs as well...

Mark Scholz, MD, is a medical oncologist who specializes exclusively in prostate cancer. Here, he gives a detailed survey of the best tools for staging newly diagnosed prostate cancer, describes the implications of the new PSMA PET scan, and answers other questions related to the diagnostic and...

Prostate-specific antigen (PSA) is one of the best-known biomarkers for screening, diagnosis, and follow-up of patients for prostate cancer. Owing to several inherent limitations with PSA, various newer blood and urinary-based biomarkers have been evaluated in pursuit of better detection and...